Initiator started off as a spin-out company from Saniona AB (“Saniona”) together with Dr. Claus Olesen, Dr. Dan Peters, Professor Ulf Simonsen and Dr. Mikael Thomsen, with the business idea of further developing a family of drug candidates based on so-called MRI technology (Monoamine Reuptake Inhibitor). The technology aims to inhibit the reuptake of monoamines in the body’s nerves and thereby increase dopamine levels in various parts of the brain and body. Dopamine is an important neurological signaling substance, and by increasing the dopamine level, a number of different diseases can be treated. All founders of Initiator have long and solid experience of preclinical and clinical drug development and are also world-leading researchers in erectile dysfunction and MRI technology, which forms the basis for the Company’s drug candidates.

Our History

Initiatorpharma-module-history-22102021

2016

  • Founding of Company ​

2017

Financial:

  • IPO Aktietorget​

IPED2015:

  • Initiator initiate Preclinical Program​

2018

IPED2015:

  • Initiator Completes Preclinical Program​
  • CTA approved for Ph1​
  • First Human Dosed in Ph1​

Financial:

  • Completion of Rights Issue​
indexpharma-2019

2019

IPED2015:

  • Ph1​ Completed​
  • Initiation of Ph2a​
  • Positive Ph2a Results Announced​

Financial:

  • Awarded IFD InnoBooster​
  • Secured Bridge ​Financing​

2020

IPED2015:

  • Final report Ph2a​

IPD2018:

  • CTA submitted for Ph2a​
  • Start screening of patients for Ph2a​
  • Exercise of Option Agreement​

Financial:

  • Direct placement Rights Share Issue​
  • Awarded IFD InnoBooster
indexpharma-2021

2021

IPED2015:

  • Approval Ph2b​
  • Start Ph2b​

Financial:

  • 30 MSEK ​Direct Investment​
  • 30 MSEK ​Preferential Rights issue​
  • Listing on Nasdaq First North Growth Market